JEMPERLI demonstrated efficacy across dMMR
recurrent or advanced
solid tumors1

Icon: JEMPERLI (dostarlimab-gxly) Response Rate

Clinically meaningful responses achieved across patients with dMMR recurrent or advanced solid tumors1

Overall response rate (n=209)
icon2

41.6%

ORR

95% CI (34.9, 48.6)

9.1%OF PATIENTS EXPERIENCED
COMPLETE RESPONSE

32.5%OF PATIENTS EXPERIENCED
PARTIAL RESPONSE

Duration of response (n=209)
calendar_icon

34.7

months (median)
(2.6, 35.8+)

95.4%
OF RESPONDERS EXPERIENCED
DURATION OF RESPONSE ≥6 MONTHS

Median follow-up for duration of response was 17.5 months measured from time of first response

The efficacy of JEMPERLI was investigated in a global, nonrandomized, multicenter, multiple cohort, open-label study of 209 patients with dMMR recurrent or advanced solid tumors who had progressed following systemic therapy and had no satisfactory alternative treatment options.* Patients received JEMPERLI 500 mg via intravenous infusion every 3 weeks for 4 doses followed by 1000 mg every 6 weeks until disease progression or unacceptable toxicity.

CI=confidence interval; dMMR=mismatch repair deficient; ORR=overall response rate.


*Patients with dMMR endometrial cancer must have progressed on or after treatment with a platinum-containing regimen. Patients with dMMR colorectal cancer must have progressed after or been intolerant to a fluoropyrimidine, oxaliplatin, and irinotecan.1

Icon: JEMPERLI (dostarlimab-gxly) Trial

Response to JEMPERLI was observed in a variety of dMMR tumor types1

  • Endometrial cancer (n=103)
  • Colorectal cancer (n=69)
  • Small intestinal cancer (n=12)
  • Gastric cancers (n=8)
  • Biliary neoplasm (n=2)
  • Liver cancer (n=2)
  • Ovarian cancer (n=2)
  • Adrenal cortical (n=1)
  • Breast cancer (n=1)
  • Genital neoplasm malignant female (n=1)
  • Pleural (n=1)
  • Unknown origin (n=1)

n values represent total population per tumor type included in the study, not number of responders.

Icon: JEMPERLI (dostarlimab-gxly) Safety

Safety profile and tolerability of JEMPERLI were evaluated in patients with dMMR recurrent or advanced solid tumors (N=267)1

9%

OF PATIENTS PERMANENTLY DISCONTINUED TREATMENT DUE TO ADVERSE REACTIONS

The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, diarrhea, and nausea
Serious adverse reactions occurred in 34% of patients receiving JEMPERLI, including (>2% of patients) abdominal pain (3.7%), sepsis (2.6%), and acute kidney injury (2.2%). Fatal adverse reaction due to respiratory failure occurred in
1 patient who received JEMPERLI
The most common adverse reaction (≥1%) leading to discontinuation was increased alanine aminotransferase (1.1%)

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

After initial 4 doses, 6-week dosing with JEMPERLI1

JEMPERLI offers a fixed-dose regimen every
6 weeks, after the initial 4 doses, every 3 weeks.

Three weeks between Dose 4 and Dose 5.

Icon: Lightbulb

Find out more about another
  indication for JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Mechanism of Action

Learn how JEMPERLI
activates T cells.

Icon: JEMPERLI (dostarlimab-gxly) Support

Get support for
JEMPERLI at every step.